Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 13Other hematologic neoplasm 6Breast 6Head & Neck 5Other 4Lymphoid 4Genitourinary 4Thoracic 3Plasma cell 3Other neoplasm 3Tumor-Agnostic 2Myeloid 2Dermatologic 2CNS 2Gynecologic 1Classical hematology 1

Conditions

Neoplasms 2

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Morphine × Tumor-Agnostic × Clear all
NCT03564548 2021-07-28

REBORN

Tetra Bio-Pharma

Phase 2 Unknown
20 enrolled
Tumor-Agnostic

Neoplasms

NCT00201539 2015-04-08

Double Bedtime Dosing During Immediate-release Morphine Administration to Cancer Patients

Norwegian University of Science and Technology

Phase 3 Completed
19 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡